David Templeton
Net worth: - $ as of 30/05/2026
Net worth: - $ as of 30/05/2026
Dr. David Templeton was previously employed as an Executive Director & Technical Director by N4 Pharma Plc, a Director-Clinical Pharmacology by Eisai Ltd. (United Kingdom), a Head-Non Clinical Development by Celltech Ltd., and a Head-Biometrics by Merck Generics Ltd.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/12/2024 | 0 ( -.--% ) | - $ | 30/05/2026 |
| Companies | Position | End |
|---|---|---|
| THALIA THERAPEUTICS PLC | Chairman | 20/05/2019 |
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Corporate Officer/Principal | 31/12/2009 |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Corporate Officer/Principal | 31/12/2003 |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Celltech Ltd.
Celltech Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development on natural science and engineering | Commercial Services |
N4 Pharma Plc
N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Merck Generics Ltd.
Merck Generics Ltd. Pharmaceuticals: MajorHealth Technology Provides therapies and drugs products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions